August 26 2020 –  Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF)  is a signal protein produced by cells that stimulates the formation of blood vessels. VEGF is a sub-family of growth factors, the platelet-derived growth factor …

Increased Risk Of Aneurysms And Artery Dissections With VEGF Inhibitors Read more »

Tagged with: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

August 23, 2019 – Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal viral disease characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (i.e., multifocal). It is caused by the JC virus, after …

Therapies that promote progressive multifocal leukoencephalopathy (PML) Read more »

Tagged with: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

24. Dezember 2010 – Swissmedic macht uns folgende Information zugänglich (Text durch den Blog-Author leicht adaptiert): Die beiden Präparate Sunitinib [Sutent] und Bevacizumab [Avastin] sind für die Behandlung bestimmter fortgeschrittener Krebserkrankungen zugelassen und haben Wirkungen auf die Tumor-Gefässbildung und damit …

Sunitinib [Sutent] und Bevacizumab [Avastin]: Kiefer-Osteonekrosen bei gleichzeitiger oder früherer Therapie mit Bisphosphonat-haltigen Arzneimitteln Read more »

Tagged with: , , , ,

December 16, 2010  –  Today, the American Food and Drug Administration notified healthcare professionals and patients that it is recommending removing the breast cancer indication for Bevacizumab [Avastin] because the drug has not been shown to be safe and effective …

Bevacizumab [Avastin]: Process for Removal of Breast Cancer Indication Begun Because of Lack of Efficacy Read more »

Tagged with: , ,